{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06632327\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab"],["pembrolizumab"],["atezolizumab"]],"indication":"stage II-IIIB resectable non-small cell lung cancer","name":"PROSPECT-LUNG","nct_id":"NCT06632327","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prospect-lung-nct06632327. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"SURGERY: Patients undergo surgery within 28 days of registration.\n\nADJUVANT THERAPY: Patients receive platinum-based doublet chemotherapy (cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and/or vinorelbine) for up to 4 cycles and immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, and/or atezolizumab) for up to 1 year in the absence of disease progression or unacceptable toxicity according to current approved guidelines.\n\nPatients also undergo CT throughout the study and may undergo MRI and/or PET/CT at screening.","label":"Arm 1 (surgery, adjuvant therapy)","type":"EXPERIMENTAL"},{"description":"NEOADJUVANT THERAPY: Within 28 days of registration, patients receive platinum-based doublet chemotherapy (cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and/or vinorelbine) for up to 4 cycles in combination with immune checkpoint inhibitor (nivolumab, pembrolizumab, and/or atezolizumab) according to current approved guidelines.\n\nSURGERY: Patients undergo surgery.\n\nADJUVANT THERAPY: Patients receive immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, and/or atezolizumab) for up to 1 year in the absence of disease progression or unacceptable toxicity according to current approved guidelines.\n\nPatients also undergo CT throughout the study and may undergo MRI and/or PET/CT at screening.","label":"Arm 2 (neoadjuvant therapy, surgery, adjuvant therapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2030-04-30","type":"ESTIMATED"},"conditions":["Resectable Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Surgical Procedure","otherNames":[],"type":"PROCEDURE"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Vinorelbine","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CT Scan","CAT Scan"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["MRI"],"type":"PROCEDURE"},{"name":"Positron Emission Tomography","otherNames":["PET Scan"],"type":"PROCEDURE"}],"last_update":"2026-09-02","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"3-year real-world event-free survival (rwEFS)","timeFrame":"From the date of randomization to the date of the first of the following events: failure to undergo resection for any reason, recurrence or progression at any time after surgery, or death from any cause, assessed at 3 years"},{"measure":"Overall survival (OS)","timeFrame":"From randomization until death from any cause, assessed up to 10 years"}],"references":[{"citation":"Booth A, Hillman S, Laumann K, Zhao YQ, LeBlanc M, Chansky K, Giri S, Dill J, Johnson J, Kelley K, Martin L, Osarogiagbon RU, Morris MJ, Chiang AC, Kozono DE, Blanke CD, Galanis E, Gray JE, Stinchcombe TE, Aljumaily R, Morgensztern D, Mandrekar SJ. PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. J Thorac Oncol. 2026 Jul;21(7):103650. doi: 10.1016/j.jtho.2026.103650. Epub 2026 Feb 24.","pmid":"41747891","type":"DERIVED"}],"start_date":{"date":"2024-12-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06632327"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prospect-lung-nct06632327"}